Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF

Blasco, María Teresa, Navas, Carolina, Martín-Serrano, Guillermo, Graña-Castro, Osvaldo, Lechuga, Carmen G., Martín-Díaz, Laura, Djurec, Magdolna, Li, Jing +21 more·2019·Cancer Cell
DOI 10.1016/j.ccell.2019.03.002

Cited by (115)

Items 101–115 of 115

  1. Additional file 9 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
    Sharma, Neha, Alok Bhushan, Jun He, Kaushal, Gagan, Bhardwaj, Vikas · 2020 · Figshare
  2. Additional file 5 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
    Sharma, Neha, Alok Bhushan, Jun He, Kaushal, Gagan, Bhardwaj, Vikas · 2020 · Figshare
  3. Additional file 6 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
    Sharma, Neha, Alok Bhushan, He, Jun, Kaushal, Gagan, Bhardwaj, Vikas · 2020 · Figshare
  4. Additional file 4 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
    Sharma, Neha, Alok Bhushan, He, Jun, Kaushal, Gagan, Bhardwaj, Vikas · 2020 · Figshare
  5. Así buscamos una cura para el cáncer de páncreas
    Mariano Barbacid · 2019
  6. Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy
    Yuanying Qian, Weikang Yan, Fan Xu, Yali Liu, Fabao Chen, Yue Lu, Zihan Zhang, Ao Gu, Ruobing Yu, Zhen Fang et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  7. Impact du dialogue entre microenvironnement et cellules cancéreuses dans l'adénocarcinome canalaire pancréatique
    Jérémy Nigri · 2020
  8. Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes
    Lisa Brunet · 2021 · theses.fr (ABES)
  9. Integrating computational chemistry and machine learning to predict KRAS mutation-induced resistance
    Katarzyna Mizgalska, Konstancja Urbaniak, Denis J. Imbody, Eric B. Haura, Wayne C. Guida, Sergio Branciamore, Aleksandra M. Karolak · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  10. Targeting pancreatic cancer with combined inhibition of EGFR and RAF
    Jakob Brandstetter, Lea Goldstein, Tim Schreiber, Rupert Palme, Tobias Lindner, Markus Joksch, Bernd Krause, Brigitte Vollmar, Simone Kumstel · 2026 · PLoS ONE
  11. RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation
    Jun Yu, Gang Yu, Yuan Liu, Yi Zhou, W.T. Liu, L Wang, Lin Liu, Yan Liu, Tiejun Pan, Zhenyu Liu et al. · 2026 · Cancer Science
  12. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer
    Yu Wang, C Liu, Song Gao, Bo Wang, Hongwei Wang, Zijian Shi, Shunjin Xia, Jiayong Li, Xiaofeng Yao, Xiaofan Guo et al. · 2026 · Nature Communications
  13. Integrating molecular dynamics and machine learning to identify potential apo-state conformational and solvent-exposure signatures associated with resistant KRAS mutants
    Katarzyna Mizgalska, Konstancja Urbaniak, Denis J. Imbody, Eric B. Haura, Wayne C. Guida, Sergio Branciamore, Aleksandra M. Karolak · 2026 · Frontiers in Chemical Biology
  14. A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor
    Theresa J. Barberi, Rahila Khuroo, Alan D. Friedman · 2026 · PLoS ONE
  15. Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy
    Yuanying Qian, Weikang Yan, Fan Xu, Yali Liu, Fabao Chen, Yue Lu, Zihan Zhang, Ao Gu, Ruobing Yu, Zhen Fang et al. · 2026 · Journal of Controlled Release